Cybin Corp. Archives - Page 2 of 3

TuesdaySep 15, 2020 12:28 pm

QualityStocksNewsBreaks – Cybin Corp. CEO Discusses Milestones, Goals and Momentum in Exciting Emerging Industry

Cybin, a life-sciences company focused on advancing psychedelic and nutraceutical-based products, today announced that its CEO, Doug Drysdale, is featured in an exclusive audio interview with NetworkNewsWire (“NNW”) – a financial news and content distribution company and one of 50+ brands in the InvestorBrandNetwork (“IBN”). During the interview, Drysdale provides insight into Cybin’s 2020 milestones, near-term goals and its efforts to build on the momentum of an industry that continues to ramp up. “We have secured a source of GMP psilocybin API to support our initial clinical program, and we’ve initiated a program to synthesize our own proprietary API to…

FridaySep 11, 2020 1:37 pm

QualityStocksNewsBreaks – Cybin Corp. Focused on Advancing New Products Amid Positive Research in Psychedelics

Cybin Corp., an exemplary Canada-based, life-science company focused on the development of pharmaceutical-grade psilocybin products, is at the forefront of change in an era open to exploring psychedelic treatment options where big pharma has failed. Started in the 1940s, but kiboshed in the 1960s with President Richard Nixon’s war on drugs, researchers have once again picked up the study of psychedelics in the treatment of mental health conditions. Research is showing positive results for many indications and disorders including depression, anxiety, PTSD, addictions, ADHD and more. A recent article discussing this reads, “Cybin believes that psychedelic substances derived from mushrooms…

TuesdaySep 01, 2020 1:25 pm

QualityStocksNewsBreaks — Cybin Corp. Names Health-Care, M&A Expert as New Chief Executive Officer

Cybin Corp., a life-sciences company advancing psychedelic pharmaceuticals, has announced that Doug Drysdale has been appointed as CEO. With more than three decades of experience, Drysdale brings invaluable insight and expertise to his new role. In 2014 as a corporate director of a NASDAQ-listed pharmaceutical company, he led the company’s recapitalization efforts, raising an estimated $65 million. Consequently, he was appointment chairman and CEO and revamped the company’s management team and board of directors while also building a 220-person sales team — all within the first year. Ultimately he grew the company’s enterprise value exponentially from $80 million to around…

MondayAug 31, 2020 12:28 pm

Cybin Corp. at Forefront of Change in Psilocybin-Based Treatments

Company focused on furthering R&D of psilocybin-based medications Cybin believes psychedelic substances derived from mushrooms can work as boosters for brain Psilocybin shows promise for an array of mental health issues Cybin Corp. is a leading life-science company focused on psychedelic and nutraceutical products to support various psychiatric and neurological conditions. The company is engaged in clinical trials, through a partnership with the Toronto Centre for Psychedelic Science (“TCPS”) to gain regulatory approval for psilocybin and other psychedelic products (http://ibn.fm/RgpQc). In the 1940s, the study of psychedelic drugs for the treatment of mental health conditions began with the discovery of LSD.…

WednesdayAug 26, 2020 2:47 pm

QualityStocksNewsBreaks – Cybin Corp. Poised Amid Groundbreaking Decision to Allow Psilocybin Therapy

Cybin Corp., an exemplary Canada-based life-science company focused on the development of pharmaceutical-grade psilocybin products, appears ideally positioned to leverage a milestone moment. Canada’s Minister of Health, the Honourable Patty Hajdu, recently approved the use of psilocybin therapy in the end-of-life treatment of four Canadians battling incurable cancer (http://ibn.fm/0BUOU), and this groundbreaking decision bodes well for companies such as Cybin, which are operating in the sector. The approval marks the first known, legal medical exemption for psilocybin use in Canada since the compound became illegal in the country in 1974. A recent article discussing this anticipates more applications through the exemption…

WednesdayAug 19, 2020 2:02 pm

QualityStocksNewsBreaks – Cybin Corp. Partners with IntelGenx to Develop Efficient Delivery Method for Pharmaceutical-Grade Psilocybin

Cybin Corp. recently announced its entry into a feasibility agreement with IntelGenx Corp., a leading drug-delivery company focused on the development and manufacturing of pharmaceutical delivery films (http://ibn.fm/TZeVy). Under the agreement, the two companies will collaborate to develop an orally dissolving, fast-acting film for the delivery of pharmaceutical-grade psilocybin. A recent article discussing this quotes Cybin’s Chief Medical Officer Dr. Jukka Karjalainen, who states, “We at Cybin are proud to be working with IntelGenx to develop a fast-acting psilocybin film. Compared to oral psilocybin capsules, which are subject to variable intestinal absorption and high first-pass metabolism in the liver, the systemic…

WednesdayAug 19, 2020 11:44 am

Cybin Corp. Ideally Positioned as Landmark Decision Regarding Psilocybin Therapy Could Spark Increased Interest, Use

Canada’s Minister of Health approves the use of psilocybin therapy in end-of-life care of four Canadians battling incurable cancer The Decision marks first legal, medical exemptions for psilocybin use in Canada since the compound became illegal in 1974 Cybin subsidiary Serenity Life Sciences focuses on advancing R&D of psilocybin-based pharmaceutical products A ground-breaking decision by Canada’s Minister of Health, the Honourable Patty Hajdu, to approve the use of psilocybin therapy in the end-of-life treatment of four Canadians battling incurable cancer (http://ibn.fm/0BUOU) bodes well for companies such as Cybin Corp., which are operating in the psilocybin sector. An exemplary Canada-based, life-sciences company,…

MondayAug 17, 2020 12:30 pm

Cybin Corp. Enters Feasibility Agreement to Develop Fast-Acting Psilocybin Film

Agreement with leading drug-delivery company outlines plans to develop fast-acting, orally dissolving film for delivery of pharmaceutical-grade psilocybin Cybin CEO notes that systemic bioavailability of film is projected to be high Cybin focused on developing fungi-derived psychedelic, medicinal products to treat mental illness, other health conditions Cybin Corp. announced that it has entered into a feasibility agreement with IntelGenx Corp., a leading drug-delivery company focused on the development and manufacturing of pharmaceutical delivery films (http://ibn.fm/TZeVy). The agreement outlines plans for the two companies to develop a fast-acting, orally dissolving film for the delivery of pharmaceutical-grade psilocybin. “We at Cybin are proud…

FridayAug 07, 2020 5:58 pm

QualityStocksNewsBreaks — Cybin Calls Approval for Psilocybin Therapy in Palliative Care Treatment a ‘Watershed Moment’

Cybin Corp., Canada's leading-edge mushroom life-sciences company, has noted its strong support for TheraPsil, a nonprofit coalition that advocates for legal, Special Access Programme ("SAP") access to psilocybin therapy for palliative care of Canadians. The coalition recently announced that Federal Minister of Health Patty Hajdu has approved the use psilocybin therapy in the end-of-life care for four Canadians diagnosed with incurable cancer. The four are the first publicly known individuals to legally use psilocybin since the compound became illegal in Canada in 1974. “This is a watershed moment for the patients involved who deserve the right to manage their health…

WednesdayAug 05, 2020 11:24 am

QualityStocksNewsBreaks – Cybin Corp. Positioned in Shifting Trend Toward Psilocybin

Cybin Corp., Canada's premier mushroom life-sciences company focused on advancing psychedelic and nutraceutical-based products, looks to be at the right place at the right time during a shifting trend toward psilocybin. Highlighting this shift, TheraPsil, a non-profit coalition that advocates for legal, compassionate access to psilocybin therapy for palliative Canadians, recently shared news that four palliative Canadians were approved for end-of-life psilocybin therapy. This approval, through section 56(1), represents the first legal medical exemptions for psilocybin in Canada since the 1970s. “I want to thank the Health Minister and Health Canada for approving my request for psilocybin use. The acknowledgement…

Site Search

Company Search

Tag: Cybin Corp.